Abstract:Background: ATRN-119 is an orally bioavailable, potent, selective macrocyclic small molecule inhibitor of Ataxia Telangiectasia and Rad3- related (ATR) kinase. As the master regulator of DNA damage response (DDR), ATR orchestrates cellular response to DNA replication stress to preserve DNA replication fork integrity. Cancer cells with markedly increased oncogenic stress or dysfunctional DDR are more reliant on ATR for genome stabilization. Thus, inhibition of ATR can result in cancer cell-selective replication fork collapse and cancer cell death. Methods: This ongoing, first-in-human, multi-site phase 1/2a trial (NCT04905914) is investigating ATRN-119 safety and pharmacokinetic properties (primary objectives), preliminary efficacy in various solid tumors (secondary objective), and biomarker profile (exploratory objective). This study uses an open-label, standard 3+3 dose escalation and dose expansion study design. Key inclusion criteria include: advanced solid tumor, measurable disease (RECIST v1.1), tumor with at least 1 DDR mutation by next-generation-sequencing, at least 1 failed standard-of-care therapy, ECOG PS 0 or 1, and adequate organ function. Key exclusion criteria are cancer therapy within 4 weeks or at least 5 half-lives, unresolved therapy-related AEs, investigational agent within 5 half-lives or 30 days of study drug, CNS metastases or unstable involvement, and concomitant treatment with strong CYP3A4 or CYP2D6 inhibitors or inducers. Results: This trial is currently enrolling at Dose level 5 (550 mg). Among 12 patients in the first four dose levels, the median age is 62 years (range: 48 to 79), where 67% (n=8) are female, 75% (n=9) are White, and 25% (n=3) are Black. The median number of prior treatments is 3 (range: 1 to 6, and 92% have received platinum-based chemotherapy). The majority of tumors, 75% (n=9), had a TP53 mutation. There have been no reports of dose-limiting toxicities, treatment-related serious adverse events (AE), and treatment-related AEs Grade 3 or higher in these cohorts. The three most commonly reported all-cause AEs are fatigue (33%, n=4), nausea (25%, n=3), and diarrhea (25%, n=3). Increasing exposure and maximum serum concentrations (Cmax) were observed by dose level. The half-life of ATRN-119 is ~5 hours. Two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg) who remains on treatment as of Day 118 (data cut off date: January 2, 2024). Conclusion: In these early cohorts, once-daily oral ATRN-119 appears to be well tolerated with a manageable safety profile, exhibits near dose proportionality, and demonstrates disease stabilization warranting further investigation. Further studies to explore a twice-daily schedule are being considered. Citation Format: Fiona Simpkins, Amit Mahipal, Patricia LoRusso, Reva Schneider, Crystal Miller, David Stenehjem, Eric J. Brown, Mike Carleton, Joachim Gullbo, Nadeem Q. Mirza. First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr CT196.

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer.

Data from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Abstract CT272: Pharmacodynamic and immunophenotyping analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

1666Tip Phase II Study of Berzosertib (M6620) + Topotecan in Patients with Relapsed Platinum-Resistant SCLC: DDRiver SCLC 250

Phase 1/2 Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Advanced Solid Tumors: Interim Results from Dose-Escalation.

STOPTRAFFIC-1: A Phase I/II Trial of SX-682 in Combination with Nivolumab for Refractory RAS-mutated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (Mcrc).

Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors

First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

A Phase Ia/Ib Study of CBP-1008, a Bispecific Ligand Drug Conjugate, in Patients with Advanced Solid Tumors

An Open-Label, Single-Arm, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Inhibitor SC0245 in Advanced Solid Malignancies.

First-in-human, Phase I Study of CBP-1008, a First-in-class Bispecific Ligand Drug Conjugate (Bi-Xdc), in Patients with Advanced Solid Tumors

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

Safety and efficacy of mitoxantrone hydrochloride liposome in patients with platinum-refractory or platinum-resistant ovarian cancer: A prospective, multicenter, open-label, single-arm, phase Ib clinical trial.

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Abstract 312: The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors